Combined Treatment for Generalized Anxiety Disorder (GAD)
2016年12月23日 更新者：Paul Crits-Christoph、University of Pennsylvania
The purpose of this study is to conduct a preliminary evaluation of the efficacy of combined medication and psychotherapy for generalized anxiety disorder (GAD).
The general goals of the current study are to conduct a late stage treatment development study.
The goal of this stage of research is to provide a preliminary answer to the question and to gather data to estimate intervention parameters (e.g., effect size, attrition rates, response rates) that would assist in planning further research.
調査の概要
詳細な説明
The specific aims of this study are to collect preliminary data relevant to the following hypotheses:
- Primary Hypothesis: Acute phase improvement for combined cognitive behavioral therapy (CBT) plus medication will be superior to medication alone.
- Secondary Hypotheses: Combined CBT plus medication will be superior to medication alone on a number of secondary outcome measures, including the core feature of GAD (worry), depressive symptoms, functional impairment, and quality of life.
- Additional Exploratory Aim: We will explore the comparative relapse rates for the combined CBT plus medication treatment and the medication alone treatment condition at 6-month follow-up.
研究の種類
介入
入学 (実際)
69
段階
- フェーズ2
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- University of Pennsylvania, 3535 Market Street, Suite 650
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
18年歳以上 (大人、高齢者)
健康ボランティアの受け入れ
いいえ
受講資格のある性別
全て
説明
Inclusion Criteria:
- GAD diagnosis by structured interview
- Hamilton Anxiety Scale score of 18 or less
- Clinical Global Impressions Scale score of at least 4
- Hamilton Depression Scale score of 18 or less
- Hamilton Depression Scale suicide item score less than 2
- Use of an effective form of contraception throughout the s
Exclusion Criteria:
- Hypersensitivity to venlafaxine XR
- History of seizures
- Episode of major depressive disorder in the previous 6 months
- History of any psychotic illness, bipolar disorder, or dementia
- Substance abuse and dependence during the past 6 months
- Other anxiety disorders with the exception of social phobia as long as GAD is primary
- Regular use of anxiolytics or antidepressants within 7 days of study onset
- Use of fluoxetine or monoamine oxidase inhibitors within 28 days of study onset (low dose usage of benzodiazepines will not prevent participation)
- Use of other psychotic medication besides benzodiazepines
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Combined Treatment
Patients who receive combined cognitive behavioral therapy (CBT) plus medication (venlafaxine XR, flexibly dosed between 75-225 mg/day) treatment for GAD.
CBT was once/week sessions for 12 weeks.
Medication continued for the full 6 months.
|
This cognitive behavioral therapy for GAD has a cognitive restructuring component and an applied relaxation component.
Patients will be educated about the nature of anxiety and be trained in the recognition and monitoring of situational, physiological, cognitive, and behavioral cues associated with anxious responding.
They will be guided through copings skill rehearsals in addition to imaginal and in vivo exposure to anxiety cues.
This cognitive behavioral treatment will consist of 1 to 1.5 hour sessions of psychotherapy, which will be held once weekly over a period of 12 weeks.
Venlafaxine XR, 75-225 mg/d, oral administration.
14 days at 75 mg/d, 150 mg/d for the remaining 6 months, 225 mg/3 for patients unimproved at week 6, tapered at 75 mg/week (this intervention is provided by protocol 709012).
他の名前：
|
|
アクティブコンパレータ：Venlafaxine XR 75-225 mg alone
These patients receive only medication treatment for GAD.
Patients take venlafaxine (flexibly dosed from 75-225 mg/day) as part of NCT00183274 and are assessed over a 6 month period.
Medication continued for the full 6 months.
|
Venlafaxine XR, 75-225 mg/d, oral administration.
14 days at 75 mg/d, 150 mg/d for the remaining 6 months, 225 mg/3 for patients unimproved at week 6, tapered at 75 mg/week (this intervention is provided by protocol 709012).
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Hamilton Anxiety Rating Scale (HAM-A)
時間枠：Data collected as part of protocol 709012 at baseline, week 2, 4, 6, 8, 12, 16, 20, and 24
|
The HAM-A was used to measure the severity of anxiety symptoms.
The scale consists of 14 items; each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate and 25-30 moderate to severe anxiety.
This measure was conducted by research psychiatrists trained and highly experienced in the use of these scales.
The evaluators were blind to group assignment.
|
Data collected as part of protocol 709012 at baseline, week 2, 4, 6, 8, 12, 16, 20, and 24
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Hospital Anxiety Depression Scale (HAD)-Anxiety Score
時間枠：Data collected as part of protocol 709012 at baseline, week 2, 4, 6, 8, 12, 16, 20, and 24
|
The HAD was used to assess patients' report of anxiety and depressive symptoms.
Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
A higher score indicates greater anxiety.
|
Data collected as part of protocol 709012 at baseline, week 2, 4, 6, 8, 12, 16, 20, and 24
|
|
Hospital Anxiety Depression Scale (HAD)-Depression Score
時間枠：Data collected as part of protocol 709012 at baseline, week 2, 4, 6, 8, 12, 16, 20, and 24
|
The HAD was used to assess patients' report of anxiety and depressive symptoms.
Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
A higher score indicates greater depression.
|
Data collected as part of protocol 709012 at baseline, week 2, 4, 6, 8, 12, 16, 20, and 24
|
|
Hamilton Rating Scale for Depression (HAM-D)-17-item Score
時間枠：Data collected as part of protocol 709012 at baseline, week 12, and week 24
|
The 17-item version of the HAM-D was used to assess severity of depressive symptoms.
Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe.
Nine are scored from 0-2.The total score is the sum of the 17 items, with a range from 0 to 50.
A higher scores indicates greater depression.
The ratings were conducted by research psychiatrists trained and highly experienced in the use of these scales.
The evaluators were blind to group assignment.
|
Data collected as part of protocol 709012 at baseline, week 12, and week 24
|
|
Clinical Global Impression (CGI)-Severity Score
時間枠：Data collected as part of protocol 709012 at baseline, week 2, 4, 6, 8, 12, 16, 20, and 24
|
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale (1=normal; 7 = extremely ill) that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis.
The ratings were conducted by research psychiatrists trained and highly experienced in the use of these scales.
Evaluators were blind to group assignment.
|
Data collected as part of protocol 709012 at baseline, week 2, 4, 6, 8, 12, 16, 20, and 24
|
|
Clinical Global Impression (CGI)-Improvement Score
時間枠：Data collected as part of protocol 709012 at baseline, week 2, 4, 6, 8, 12, 16, 20, and 24
|
The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale (1= very much improved; 7 = very much worse) that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.
The ratings were conducted by research psychiatrists trained and highly experienced in the use of these scales.
Evaluators were blind to group assignment.
|
Data collected as part of protocol 709012 at baseline, week 2, 4, 6, 8, 12, 16, 20, and 24
|
|
Quality of Life Subscale of the General Health Questionnaire (GHQ)
時間枠：Data collected as part of protocol 709012 at baseline, week 12, and week 24
|
The General Health Questionnaire (GHQ) is a psychometric screening tool to identify common psychiatric conditions.
Patients completed the 12 quality of life questions (each on a 0 to 3 scale) on this questionnaire.
Scores on the 12 items were added up to create summary score (range = 0 to 36).
Higher scores indicate worse health.
|
Data collected as part of protocol 709012 at baseline, week 12, and week 24
|
|
Penn State Worry Questionnaire (PSWQ)
時間枠：Data collected as part of protocol 709012 at baseline, week 12, and week 24
|
The Penn State Worry Questionaire is a 16-item inventory that aims to measure the trait of worry, using Likert rating from 1 (not at all typical of me) to 5 (very typical of me).
A total score is calculated (range = 16 to 80), with higher scores indicating greater worry.
|
Data collected as part of protocol 709012 at baseline, week 12, and week 24
|
|
Physical Component Score of the 12-Item Short Form Survey (SF-12)
時間枠：Data collected as part of protocol 709012 at baseline, week 12, and week 24
|
The Short Form (12) Health Survey is a 12-item, patient-reported survey of patient health.
Physical and Mental Health Component Scores (PCS & MCS) are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.
|
Data collected as part of protocol 709012 at baseline, week 12, and week 24
|
|
Mental Component Score of the 12-item Short Form Survey (SF-12)
時間枠：Data collected as part of protocol 709012 at baseline, week 12, and week 24
|
The Short Form (12) Health Survey is a 12-item, patient-reported survey of patient health.
Physical and Mental Health Component Scores (PCS & MCS) are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.
|
Data collected as part of protocol 709012 at baseline, week 12, and week 24
|
|
Clinical Response Rate
時間枠：Data collected as part of protocol 709012 at baseline, week 2, 4, 6, 8, 12, 16, 20, and 24
|
Clinical response on the HAM-A was defined as a 50% or greater reduction from baseline to last value with the 24-week open label medication phase.
|
Data collected as part of protocol 709012 at baseline, week 2, 4, 6, 8, 12, 16, 20, and 24
|
|
50 Percent or Greater Reduction in PSWQ Score
時間枠：Data collected as part of protocol 709012 at baseline, week 12, and week 24
|
Clinically significant change was defined on the PSWQ as an estimated (based on linear mixed effects model) endpoint score of less than 50.9.
This score was calculated using the PSWQ normative data provided by Gillis, Haaga, and Ford (1995) and the baseline PSWQ mean and standard deviation (SD) from the current sample.
The PSWQ mean and SD from the normative and current GAD samples were entered into the Jacobson et al. (1984) formula "c" for clinically significant change.
This method provides a cutoff indicating whether or not the level of functioning by a patient is statistically more likely to be in the functional rather than the dysfunctional population.
|
Data collected as part of protocol 709012 at baseline, week 12, and week 24
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
捜査官
- 主任研究者：Paul Crits-Christoph, PhD、University of Pennsylvania
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始
2006年10月1日
一次修了 (実際)
2008年3月1日
研究の完了 (実際)
2008年3月1日
試験登録日
最初に提出
2008年2月7日
QC基準を満たした最初の提出物
2008年2月7日
最初の投稿 (見積もり)
2008年2月21日
学習記録の更新
投稿された最後の更新 (実際)
2017年2月16日
QC基準を満たした最後の更新が送信されました
2016年12月23日
最終確認日
2016年12月1日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 802307
- 5R34MH072678-02 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。